timothy sykes logo
SYRE Stock Pops As Stifel Hikes Target Ahead Trial Catalysts Thumbnail
ADD US ONG Google News

SYRE Stock Pops As Stifel Hikes Target Ahead Trial Catalysts

JACK KELLOGG•UPDATED APR. 13, 2026, 11:33 AM ET
Reviewed by Tim Sykes Fact-checked by Ellis Hobbs

Spyre Therapeutics Inc. stocks have been trading up by 18.93 percent after bullish sentiment on its pipeline and partnership progress.

Candlestick Chart

Live Update At 11:32:45 EDT: On Monday, April 13, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 18.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Spyre Therapeutics, trading as SYRE, has been on a sharp multi-week climb that traders in this niche live for. In mid‑March, SYRE closed near $41–43. By 2026/04/02, it was printing around $47–48, then broke into the low $50s over the next week. The most recent daily bar shows a wild session: a $67 open, a spike to $75, a flush to about $59, and a close near $61. That’s textbook high-volatility, catalyst-driven action.

Intraday, SYRE’s 5‑minute chart shows heavy range between $59 and $68, with multiple failed pushes above $66–67 and buyers stepping in around $60. For short-term trading, that $60 zone is acting like a key intraday pivot where dip-buyers test their conviction.

On fundamentals, SYRE is early‑stage biotech: no product revenue, heavy R&D, and negative earnings. The latest report shows about $85.7M in cash and $756.5M in cash plus short‑term investments, backed by a very strong current ratio of 13.3 and no long‑term debt. Returns on capital are deeply negative, which is normal for a clinical‑stage name burning cash to push trials forward. For active traders, that setup—big cash cushion plus looming data—creates a classic “story stock” backdrop where news flow, not earnings, drives the tape.

Why Traders Are Watching SYRE’s Trial Cadence

SYRE is grabbing trader attention because the story is lining up with the chart. Stifel’s move to lift its price target from $70 to $92, while sticking with a Buy rating, tells the Street that Spyre Therapeutics is not just another small biotech swinging in the dark. The call is anchored on TL1A‑targeted therapies in inflammatory bowel disease and related conditions, plus a dense run of clinical readouts ahead.

The core of the story is execution. SYRE completed enrollment ahead of expectations in the rheumatoid arthritis arm of its SKYWAY Phase 2 basket trial for TL1A antibody SPY072. When a company finishes enrollment early, it shortens the time to data. For SYRE, that pulls rheumatoid arthritis topline results into Q3 2026, turning what might have been a distant event into a live trading catalyst on many watchlists.

At the same time, Spyre Therapeutics has kept the psoriatic arthritis and axial spondyloarthritis arms of SKYWAY on schedule for Q4 2026 readouts. The market already responded: SYRE shares jumped more than 6% on the clinical update, confirming that traders are dialed into this timeline.

On the gastrointestinal side, the SKYLINE ulcerative colitis platform trial of SPY001 is enrolling ahead of plan, with first data expected in Q2 2026 and Part A induction topline results in moderate‑to‑severe ulcerative colitis set for 2026/04/13. That specific date is now a red‑circle event for SYRE. Good data there would not just move the stock; it could reset how traders value the entire TL1A platform.

Meanwhile, option grants to new non‑executive employees and routine Form 4 insider activity look like background noise—typical biotech housekeeping—next to that catalyst stack.

More Breaking News

Conclusion

For active traders, SYRE now sits at the intersection of strong news, heavy volatility, and a clear calendar of binary events. The chart shows aggressive expansion from the low $40s into the $60s and $70s, while intraday action highlights a tug‑of‑war around the $60–67 band. That kind of tape often follows when the Street starts handicapping big upcoming readouts instead of arguing about current earnings.

Fundamentally, Spyre Therapeutics is still burning cash, with negative earnings and hefty R&D spend, but the balance sheet carries a sizable cash and securities pile and no long‑term debt. That gives SYRE room to run its SKYLINE and SKYWAY programs without an immediate funding crunch, which matters when traders are weighing dilution risk against upside from data.

The key dates are now front and center: 2026/04/13 for SKYLINE Part A induction results in ulcerative colitis, Q2 2026 for initial SKYLINE data, Q3 2026 for rheumatoid arthritis topline in SKYWAY, and Q4 2026 for the psoriatic arthritis and axial spondyloarthritis arms. Layer Stifel’s $92 target on top, and you have a name that will stay on many watchlists.

As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful ones.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” With SYRE, preparation means knowing the catalyst calendar cold, respecting the volatility on the chart, and having a concrete trading plan before the headlines hit. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SYRE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”